Phaseline

Companies › Immatics US

Immatics US: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMA203 (anzutresgene autoleucel, anzu-cel)
PRAME-redirected CAR-T cell therapy
PRAMEPhase 3Melanoma, Cutaneous Malignant; Refractory Cancer; Cutaneous MelanomaJan 2028
IMA203CD8
ACTengine autologous T-cell therapy targeting PRAME
–Phase 1Refractory CancerDec 2028
mRNA-4203
mRNA vaccine (adjunctive immunotherapy)
–Phase 1Cutaneous MelanomaAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06743126IMA203 (anzutresgene autoleucel, anzu-cel)Phase 3Melanoma, Cutaneous MalignantOncologyJan 2028
NCT03686124IMA203 (anzutresgene autoleucel, anzu-cel)Phase 1Refractory CancerOncologyDec 2028
NCT03686124IMA203CD8Phase 1Refractory CancerOncologyDec 2028
NCT06946225mRNA-4203Phase 1Cutaneous MelanomaOncologyAug 2029
NCT06946225IMA203 (anzutresgene autoleucel, anzu-cel)Phase 1Cutaneous MelanomaOncologyAug 2029

Targets

PRAME (1)

Companies with the same targets

Immunocore Neowise Biotechnology PDC*line Pharma SAS

Companies built like this

Takara Bio Tesaro Immunocore HRYZ Biotech Erasca

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.